VistaGen Therapeutics Inc
NASDAQ:VTGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Richmond Mutual Bancorporation Inc
NASDAQ:RMBI
|
US |
|
Zhejiang Sanfer Electric Co Ltd
SSE:605336
|
CN |
|
B
|
Bergs Timber AB (publ)
STO:BRG B
|
SE |
|
R
|
Redington (India) Ltd
NSE:REDINGTON
|
IN |
|
Natwest Group PLC
LSE:NWG
|
UK |
|
Shandong Daye Co Ltd
SSE:603278
|
CN |
|
Heritage Foods Ltd
NSE:HERITGFOOD
|
IN |
|
Moury Construct SA
LSE:0NZS
|
BE |
VistaGen Therapeutics Inc
Non-Reccuring Items
VistaGen Therapeutics Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
VistaGen Therapeutics Inc
NASDAQ:VTGN
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Non-Reccuring Items
-$5.9B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Non-Reccuring Items
-$1.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Non-Reccuring Items
-$7.1B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-61%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Non-Reccuring Items
-$512m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-72%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Non-Reccuring Items
-$297m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-32%
|
|
VistaGen Therapeutics Inc
Glance View
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California and currently employs 31 full-time employees. The company went IPO on 2010-10-18. The firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The firm's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).
